Michael Martino made CEO of Ambit Biosciences
This article was originally published in Scrip
Ambit Biosciences, a privately-held biopharma developing a pipeline of small kinase inhibitors for the treatment of cancer, inflammatory disease and other indications, has appointed Michael Martino president, CEO and a member of the board of directors. He replaces Dr Alan Lewis who announced his departure earlier this year and recently left the company. Mr Martino was most recently the first CEO of Arzeda, and previously served as president and CEO of Sonus Pharmaceuticals, a cancer therapeutics company.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.